Form: 20-F

Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

1

 

Exhibit 4.21

Certain information identified by [***] has been omitted from this exhibit because it is both not material and is the type that the registrant treats as confidential.

 

LOGO

Licence Agreement

Date

 

 

21 March 2024

Parties

 

1.

Kazia Therapeutics Ltd ABN 37 063 259 754 of Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney, New South Wales, Australia 2000 (Kazia)

 

2.

Sovargen Co. Ltd. Business Registration number 475-81-01158 (a company organised under the laws of the Republic of Korea) of Annex B/D No.2, 193 Munji-ro, Yuseong-gu, Daejeon, Republic of Korea 34051 (Sovargen)

Background

 

A.

Kazia is developing paxalisib (also known as GDC-0084), a proprietary PI3K/AKT/mTOR pathway inhibitor, for the treatment of glioblastoma and certain other cancers, and owns or controls certain Patents, Know-how and other Intellectual Property Rights relating to such product candidate.

 

B.

Sovargen wishes to obtain from Kazia, and Kazia is willing to grant to Sovargen, licences to Develop and Manufacture paxalisib and the Product, and Commercialise the Product, in the Field in the Territory, on the terms and conditions set out in this Agreement.

Agreed terms

 

1.

Definitions and interpretation

 

1.1

Definitions

 

 

In this Agreement:

 

 

Affected Party has the meaning given to that term in clause 18.1.

 

 

Affiliate means any person that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a party. For the purposes of this definition, “control” means:

 

  (a)

the direct or indirect ownership of more than 50% of the voting stock or other voting interests or interest in the profits of the party; or

 

  (b)

the ability to otherwise control or direct the decisions of board of directors or equivalent governing body thereof.

 

 

Agreement means this agreement including the background, any schedules and any annexures.

 

 

Alliance Manager has the meaning given to that term in clause 3.1(a).

 

 

Alliance Manager Meeting has the meaning given to that term in clause 3.1(d).

 

 

Auditor has the meaning given to that term in clause 9(b).

 

 

Business Day means a day that is not a Saturday, Sunday or public holiday in Sydney, Australia, or Seoul, Korea.


2

 

 

Claim means a claim, notice, demand, action, proceeding, litigation, prosecution, arbitration, investigation, judgment, award, damage, loss, cost, expense or liability however arising, whether present, unascertained, immediate, future or contingent, whether based in contract, tort or statute and whether involving a Third Party or a party or otherwise.

 

 

Commercialisation means all activities directed to marketing, distributing, selling, importing and/or exporting the Product, including all activities directed to obtaining pricing and reimbursement approvals for the Product and Commercialise shall have a corresponding meaning.

 

 

Commercially Reasonable Efforts means, with respect to the Development of the Compound and the Product, and Commercialisation of the Product, under this Agreement, those efforts consistent with the exercise of prudent scientific and business judgment as would be applied by an experienced party that is within the same industry as the party to this Agreement that bears the performance obligation to the development and commercialization of that company’s product that is at a similar stage of development or commercialization and has similar market potential, taking into account efficacy, safety, Patent and regulatory exclusivity, anticipated or approved labelling, present and future market potential, competitive market conditions, the profitability of the product in light of pricing and reimbursement issues, and all other relevant factors. Commercially Reasonable Efforts will be determined on a market-by-market and indication-by-indication basis, and it is anticipated that the level of effort required may be different for different markets and indications and may change over time, reflecting changes in the status of the Compound and the Product and markets involved.

 

 

Compound means paxalisib (also known as GDC-0084) with any salt, polymorph, hydrate, solvate or metabolite, as set out in Schedule 1.

 

 

Confidential Information means:

 

  (a)

the terms of this Agreement and its subject matter, including Information submitted or disclosed by a party during negotiations, discussions and meetings relating to this Agreement;

 

  (b)

Information that at the time of disclosure by a Disclosing Party is identified to the Receiving Party as being confidential; and

 

  (c)

all other Information belonging or relating to a Disclosing Party, or any Affiliate of that Disclosing Party, that is not generally available to the public at the time of disclosure other than by reason of a breach of this Agreement or which the Receiving Party knows, or ought reasonably to be expected to know, is confidential to that Disclosing Party or any Affiliate of that Disclosing Party.

 

 

Consequential Loss means any indirect, incidental, special or consequential loss or damage, pure economic loss damages and exemplary or punitive damages, including loss or damage in relation to loss of use, loss of production, loss of revenue, loss of profits or anticipated profits, loss of business, loss of business opportunity, loss of contract, loss of reputation or opportunity, business interruptions of any nature, loss of data, data corruption rectification costs or loss or damage resulting from wasted management time.

 

 

Controlled means, with respect to any Intellectual Property Rights, that a party has the legal authority or right (whether by ownership, licence or otherwise) to grant a licence, sub-licence, access or other right (as applicable) under such Intellectual Property Rights to the other party on the terms and conditions of this Agreement, in each case without breach of the terms of any agreement with a Third Party and Control shall have a corresponding meaning.

 

 

Default Notice has the meaning given to that term in clause 16.3(a).

 

 

Defaulting Party has the meaning given to that term in clause 16.3(a).

 

 

Development means, with respect to the Compound or a Product, all activities directly relating to research, pre-clinical manufacturing and control, nonclinical or clinical development undertaken in order to file and maintain a regulatory filing or to obtain Regulatory Approvals for the Product, including conducting pre-clinical studies and clinical studies (and any research to design clinical studies), managing regulatory affairs and the preparation, submission and maintenance of registration filings and approvals and Develop shall have a corresponding meaning.


3

 

 

Development Milestone Amount means, for each Development Milestone Event, the corresponding amount set out in column 2 of the table in Schedule 3.

 

 

Development Milestone Event means an event set out in column 1 of the table in Schedule 3.

 

 

Disclosing Party means the party to whom Information belongs or relates.

 

 

Dispute has the meaning given to that term in clause 17.1.

 

 

Dispute Notice has the meaning given to that term in clause 17.1.

 

 

Effective Date means 21 March 2024.

 

 

Expert has the meaning given to that term in Schedule 4.

 

 

FDA means the United States of America’s Food and Drug Administration.

 

 

Field means the treatment of mTORopathy (PI3K/AKT/mTOR) related non-cancerous diseases of the central nervous system, including but not limited to focal cortical dysplasia and tuberous sclerosis complex disease, where mTORopathy is defined as a medical condition or disorder related to or caused by disruption or mutations in the mechanistic target of rapamycin (mTOR) pathway.

 

 

Financial Dispute has the meaning given to that term in Schedule 4.

 

 

First Commercial Sale means, with respect to a Product in the Field in a country in the Territory, the first sale of such Product in the Field by Sovargen, its Affiliates or sub-licensees to a Third Party for distribution, use or consumption in such country after a Marketing Authorisation for the Product in the Field has been obtained in such country.

 

 

Force Majeure Event means any act, event or cause including:

 

  (a)

an act of God, peril of the sea, accident of navigation, war, sabotage, riot, act of terrorism, insurrection, civil commotion, national emergency (whether in fact or law), martial law, fire, lightning, flood, cyclone, earthquake, landslide, storm or other adverse weather conditions, explosion, power shortage, strike or other labour difficulty (whether or not involving employees of the party concerned), epidemic, pandemic, public health emergency, quarantine, disruptions to supply chain, radiation or radioactive contamination; or

 

  (b)

an action or inaction of a Government Agency, including expropriation, restraint, prohibition, intervention, requisition, requirement, direction or embargo by legislation, regulation, decree or other legally enforceable order,

 

 

to the extent that the act, event or cause directly results in the Affected Party being prevented from or delayed in performing one or more of its material obligations under this Agreement and that act, event or cause is beyond the reasonable control of the Affected Party.

 

 

Genentech means Genentech Inc.

 

 

Genentech Agreement means the Exclusive Licence Agreement between Kazia and Genentech dated 25 October 2016.

 

 

Government Agency means any government or any public, statutory, governmental (including a local government), semi-governmental or judicial body, entity, department or authority and includes any self-regulatory organisation established under statute.

 

 

Information means any information, whether oral, graphic, electronic, written or in any other form, including:

 

  (a)

forms, memoranda, letters, specifications, processes, procedures, statements, formulae, technology, inventions, trade secrets, research and development information, know how, designs, plans, photographs, microfiche, business records, notes, accounting procedures or financial information, sales and marketing information, names and details of customers, suppliers and agents, employee details, reports, drawings and data;


4

 

  (b)

copies and extracts made of or from that information and data, whether translated from the original form, recompiled, partially copied, modified, updated or otherwise altered; and

 

  (c)

samples or specimens (if any) disclosed either before or after execution of this Agreement.

 

 

Improvement means any improvement, enhancement, modification, adaptation, extension, development, mutation, application of and all other technical advances made by or on behalf of a person, whether or not protected by statute.

 

 

Insolvency Event means, in respect of a party, the occurrence of any one or more of the following events or circumstances:

 

  (a)

its winding up, liquidation or provisional liquidation;

 

  (b)

the appointment of a controller or analogous person to it or any of its property;

 

  (c)

being deregistered as a company or other body corporate or otherwise dissolved;

 

  (d)

being unable to pay any of its debts as and when due and payable or being deemed to be insolvent under any Law;

 

  (e)

seeking protection from its creditors under any Law or entering into a compromise, moratorium, assignment, composition or arrangement with, or for the benefit of, any of its members or creditors; or

 

  (f)

an analogous event or circumstance to any listed above occurs in any jurisdiction,

 

 

unless such event or circumstance occurs as part of a solvent reconstruction, amalgamation, compromise, arrangement, merger or consolidation approved by the party (which approval is not to be unreasonably withheld or delayed).

 

 

Intellectual Property Rights means all present and future intellectual and industrial property rights conferred by statute, at common law or in equity and wherever existing, including:

 

  (a)

patents, inventions, designs, copyright, trademarks, brand names, product names, domain names, rights in circuit layouts, plant breeder’s rights, know how, trade secrets and any other rights subsisting in the results of intellectual effort in any field, whether or not registered or capable of registration;

 

  (b)

any application or right to apply for registration of any of these rights;

 

  (c)

any registration of any of those rights or any registration of any application referred to in paragraph (b); and

 

  (d)

all renewals, divisions and extensions of these rights.

 

 

Kazia Indemnitee has the meaning given to that term in clause 14.2.

 

 

Kazia Product means the pharmaceutical product that contains the Compound as an active pharmaceutical ingredient that has been Manufactured by or on behalf of Kazia and supplied to Sovargen solely for the purpose of conducting pre-clinical studies and clinical trials in the Territory.

 

 

Know-How means any technical, commercial, scientific, regulatory or practical information, including discoveries, improvements, modifications, processes, methods, protocols, formulas, data, inventions, know-how and trade secrets, patentable or otherwise, but excluding any Patents.

 

 

Launch Date means the date that a Product is first made available for commercial sale in the Field in the Territory.

 

 

Law means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, the rules of the security exchange on which a party’s or its Affiliate’s stock is publicly traded, or any order by any Government Agency, or any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law.


5

 

 

Licenced IP means:

 

  (a)

the Licenced Know-How; and

 

  (b)

the Licenced Patents,

 

 

and includes any Improvements to the above.

 

 

Licenced Know-How means all Know-How that:

 

  (a)

is Controlled by Kazia or its Affiliates as at the Effective Date or at any time during the Term; and

 

  (b)

is necessary for:

 

  (i)

the Development of the Product; or

 

  (ii)

the Manufacture or Commercialisation of the Product.

 

 

Licenced Patents means all Patents that:

 

  (a)

are Controlled by Kazia or its Affiliates as at the Effective Date or at any time during the Term; and

 

  (b)

claim or cover the Product (including composition of matter, methods of making and using),

 

 

with, the Licenced Patents existing as at the Effective Date set out in Schedule 2.

 

 

London Inter-bank Offered Rate means the benchmark interest rate at which a selection of banks in London are prepared to lend to one another in USD, as published by the Intercontinental Exchange, Inc.

 

 

Manufacture means all activities related to producing any quantity of the Compound or the Product, including the manufacture, export, receipt, inspection, storage, handling of materials, processing, purification, packaging, labelling, warehousing, quality control testing, shipping and release of the Compound or the Product and Manufacturing shall have a corresponding meaning.

 

 

Marketing Authorisation means a Regulatory Approval issued by a Regulatory Authority for the importation, promotion, marketing, selling and supply the Product in a country in the Territory, and all approved supplements, amendments and revisions of the same.

 

 

Net Sales means the gross amount received by Sovargen, its Affiliates or sub-licensees for sale of the Product to Third Parties (other than Sovargen’s sub-licensees) less the following amounts incurred or paid by the selling party in connection with the sale of the Product:

 

  (a)

normal and customary trade, cash and quantity discounts (other than early payment cash discounts) charge-back payments, allowances or rebates actually taken and allowed (including promotional or similar discounts or rebates and rebates to governmental or managed care organisations);

 

  (b)

customary discounts provided in connection with coupon, voucher or similar patient programs;

 

  (c)

credits or allowances actually granted to the customer for damaged goods, returns, recalls, rebates or rejections of the Product;

 

  (d)

taxes (including sales tax and VAT, but not income taxes), tariff, duty or governmental charges levied on the sales, transfer, transportation or delivery of the Product included on the invoice for the Product and not reimbursed directly or indirectly;

 

  (e)

reasonable charges for insurance, freight, and other transportation costs directly related to the delivery of the Product to the extent such charges were included on the invoice provided to the Third Party;


6

 

  (f)

customary administrative fees paid to group purchasing organisations or managed health care organisations or managed care entities for sale of the Product; and

 

  (g)

any amounts invoiced for sales of Product supplied free-of-charge for: (i) use in clinical trials of the Product, (ii) use under early access programs; (iii) compassionate use; (iv) named patient, indigent access; or (v) patient assistance programs.

 

 

Where Sovargen is considering or intends to supply or sell Product in a country in the Territory as a bundle with any other product or products for the one (combined) price (Bundle), then Sovargen must provide prior notice to Kazia, and Sovargen and Kazia must agree how the price (including gross amount and Net Sales) of the Product in the Bundle should be allocated for the purposes of this Agreement prior to the first such sale or supply. For the avoidance of doubt, no such sale or supply can occur without such agreement being reached.

 

 

Patent means a patent or a patent application, including any divisions, continuations, continuations-in-part, invention certificates, substitutions, reissues, re-examinations, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above.

 

 

Patentable Improvements has the meaning given to that term in clause 2.4(c).

 

 

Performance Milestone has the meaning given to that term in clause 4.1(c).

 

 

Performance Milestone Report has the meaning given to that term in clause 4.1(d).

 

 

Product means any pharmaceutical product that contains the Compound as an active pharmaceutical ingredient, in any formulation or dosage form and for any mode of administration, [***].

 

 

Product PDV has the meaning given to that term in clause 7(a).

 

 

Receiving Party means the party to whom Information is disclosed or who possesses or otherwise acquires Information belonging or relating to a Disclosing Party.

 

 

Regulatory Approval means with respect to a Product, all registrations, approvals, permits, authorisations or licences issued by an applicable authority in a jurisdiction that are necessary for the Manufacture, importation, export, storage, promotion, marketing, sale, distribution or other Development or Commercialisation of that Product in the relevant jurisdiction (including applicable approvals of labelling for that product in that jurisdiction and any customs and tax approvals, but excluding any price and reimbursement approval) and including any amendment or supplement of the same.

 

 

Regulatory Authority means any applicable Government Agency responsible for granting Regulatory Approvals for the Product.

 

 

Regulatory Materials means any regulatory application, submission, notification, communication, correspondence, registration and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to Develop or Manufacture the Compound or the Product, or Commercialise the Product, in a particular country or jurisdiction.

 

 

Review Period has the meaning given to that term in clause 6.5(a).

 

 

Royalty Query has the meaning given to that term in clause 6.5(a).

 

 

Royalty Report has the meaning given to that term in clause 6.3(a).

 

 

Royalty Term has the meaning given to that term in clause 6.1.

 

 

Sovargen Indemnitee has the meaning given to that term in clause 14.1.

 

 

Subsequent Indication means a separate and distinct disease, disorder or medical condition for which a Product can be used to diagnose, treat or prevent, which use is the subject of:

 

  (a)

a Marketing Authorisation separate to the first Marketing Authorisation obtained for a Product in the Field in the Territory; or


7

 

  (b)

a separate approval within the first Marketing Authorisation obtained for the Product in the Field in the Territory which has required an additional clinical trial to those upon which the first Marketing Authorisation was granted.

 

 

Supply Agreement has the meaning given to that term in clause 4.5(a).

 

 

Term has the meaning given to that term in clause 16.1.

 

 

Territory means all countries worldwide, other than mainland China, Hong Kong, Macao and Taiwan.

 

 

Third Party means a person who is not Kazia, Sovargen, their respective Affiliates or a sub-licensee of Sovargen.

 

 

Valid Claim means a claim of:

 

  (a)

an issued and unexpired Patent included within the Licenced Patents, unless the claim has been held unenforceable or invalid by the final, un-reversed, and un-appealable decision of a court or other Government Agency of competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally admitted or determined to be invalid, un-patentable or unenforceable, whether through reissue, re-examination, disclaimer or otherwise; or

 

  (b)

a pending patent application within the Licenced IP to the extent the claim continue to be prosecuted in good faith and has not been pending for more than 7 years following the expiration of the last claim under paragraph (a) above.

 

 

USD means U.S. dollar, being the official currency of the United States of America.

 

1.2

Interpretation

 

 

In this Agreement, unless the context requires otherwise:

 

  (a)

the singular includes the plural and vice versa;

 

  (b)

a gender includes the other genders;

 

  (c)

headings are used for convenience only and do not affect the interpretation of this Agreement;

 

  (d)

other grammatical forms of a defined word or expression have a corresponding meaning;

 

  (e)

a reference to a document is to that document as amended, novated, supplemented, extended or restated from time to time;

 

  (f)

a reference to a party is to a party to this Agreement and includes that party’s executors, administrators, successors, permitted assigns and permitted substitutes;

 

  (g)

if something is to be or may be done on a day that is not a Business Day then it must be done on the next Business Day;

 

  (h)

“person” includes a natural person, partnership, body corporate, association, joint venture, governmental or local authority, and any other body or entity whether incorporated or not;

 

  (i)

“month” means calendar month, “calendar quarter” means a period of 3 months ending on 31 March, 30 June, 30 September and 31 December, “year” means 12 consecutive months and “calendar year” means a period of 12 months ending on 31 December;

 

  (j)

a reference to a thing (including a right) includes a part of it but nothing in this clause implies that part performance of an obligation constitutes performance of that obligation;

 

  (k)

a reference to all or any part of a statute, rule, regulation or ordinance (statute) is to that statute as amended, consolidated, re-enacted or replaced from time to time;

 

  (l)

a reference to a clause, item or schedule is to a clause, item or schedule of this Agreement;


8

 

  (m)

“include”, “for example” and any similar expressions are not used, and must not be interpreted, as words of limitation;

 

  (n)

money amounts are stated in USD unless otherwise specified;

 

  (o)

a reference to a time of day is to that time in Sydney, Australia; and

 

  (p)

a reference to any agency or body that ceases to exist, is reconstituted, renamed or replaced, or has its powers or functions removed (defunct body) is to the agency or body that performs most closely the powers or functions of the defunct body.

 

2.

Grant of licences

 

2.1

Licence to Sovargen

 

 

In consideration of the payments under this Agreement, Kazia grants to Sovargen:

 

  (a)

a royalty bearing, sub-licensable exclusive licence for the Term to the Licenced Patents to Develop the Compound and the Product, make, have made, use, sell, offer for sale, have sold, import, Manufacture and Commercialise the Product, in the Field in the Territory;

 

  (b)

a royalty bearing, sub-licensable non-exclusive licence for the Term to the Licenced Patents to Manufacture the Compound in the Territory; and

 

  (c)

a royalty bearing, sub-licensable non-exclusive licence for the Term to the Licenced Know-How to Develop and Manufacture the Compound and Product, and to Commercialise the Product, in the Field in the Territory.

 

2.2

Sub-licence

 

 

Sovargen may sub-licence any of its rights in the Territory provided that:

 

  (a)

at least 20 Business Days prior to entering into such sub-licence, Sovargen provides details to Kazia of the proposed sub-licensee and considers, in good faith, any requests provided by Kazia in relation to the proposed sub-licensee, including a request that Sovargen not enter into a sub-licence with such proposed sub-licensee;

 

  (b)

Sovargen satisfies itself on reasonable grounds that any proposed sub-licensee is solvent and has the commercial and technical capability and appropriately trained and skilled resources to perform its obligations under the sub-licence;

 

  (c)

the sub-licensee first agrees in writing to be subject to, and bound by, where applicable, terms and conditions substantially similar to the terms and conditions of this Agreement;

 

  (d)

Sovargen will be responsible for the payment of all amounts due under this Agreement; and

 

  (e)

Sovargen will remain responsible to Kazia for all acts performed by the sub-licensee pursuant to any such sub-licence agreement and must ensure compliance by the sub-licensee with the obligations of Sovargen under this Agreement such that any act or omission of sub-licensee which if performed by Sovargen would be a breach of this Agreement will be deemed to be an act or omission of Sovargen and a breach of this Agreement.

 

2.3

Licence back to Kazia

 

  (a)

Notwithstanding the exclusive licence granted to Sovargen under clause 2.1(a), Sovargen grants back to Kazia a royalty-free, sub-licensable, non-exclusive licence, irrevocable for the Term, to the Licenced Patents solely for the purposes of conducting non-clinical research of the Compound and Product in the Field in the Territory.

 

  (b)

For the avoidance of doubt, Sovargen acknowledges and agrees that Kazia retains the exclusive rights (as between the parties) to practice, licence and otherwise exploit the Licenced IP outside the scope of the licences granted to Sovargen in clause 2.1.


9

 

2.4

Improvements to the Licenced IP

 

  (a)

Each party must notify the other of any Improvements discovered or developed by it or on its behalf with respect to any of the Licenced IP as soon as possible, and no later than 10 Business Days from the discovery or development.

 

  (b)

Subject to clause 2.4(c), all rights, title and interest in Improvements to any of the Licensed IP developed or discovered by or on behalf of Sovargen or Kazia vest in (as between the parties) Kazia, and Sovargen hereby assigns to Kazia, by way of both present and future assignment and without any encumbrance, all Intellectual Property Rights in such Improvement made by or on behalf of Sovargen to the Licenced IP.

 

  (c)

Notwithstanding clause 2.4(b), all rights title and interest in any Improvements to any of the Licensed IP developed or discovered by or on behalf of Sovargen which are deemed to possess novelty and inventiveness recognized by a patent office of competent jurisdiction (Patentable Improvements) shall vest solely in Sovargen, provided that Sovargen solely contributes to the conception thereof in accordance with the definition of inventorship under U.S. patent law. For the avoidance of doubt, any comments provided by Kazia, for instance, but not limited to, during Alliance Manager Meeting or in relation to reports, proposed protocol, or material protocol amendments shall not constitute contributions to Patentable Improvements.

 

  (d)

Each party agrees to do all reasonable things and execute all necessary documents, as and when reasonably required by the other party and at the other party’s cost, to give effect to clauses 2.4(b) and 2.4(c).

 

  (e)

Sovargen, at Kazia’s expense and upon reimbursing Sovargen’s out-of-pocket expenses for patent prosecution, must grants to Kazia a sub-licensable, perpetual, irrevocable, non-exclusive licence to the Patentable Improvements for use in relation to the Compound and any product containing the Compound within the Field, outside the Territory only.

 

  (f)

The parties agree that upon creation of any Improvement to any of the Licenced IP under clause 2.4(b), the Improvement will become part of the Licenced IP. For the avoidance of doubt, Improvements under clause 2.4(c) shall vest in Sovargen, and will not become part of the Licensed IP.

 

2.5

Improvements to other Intellectual Property Rights

 

 

For the avoidance of doubt:

 

  (a)

any Improvement in or to any Intellectual Property Rights owned by or licensed to Sovargen other than in accordance with this Agreement will, as between the parties, automatically vest in Sovargen; and

 

  (b)

without derogating from clause 2.4(b), and subject to clause 2.4(c), any Improvement in or to any Intellectual Property Rights owned by or licensed to Kazia will automatically vest in Kazia.

 

2.6

No implied licences

 

 

The parties acknowledge and agree that the licences granted under this clause 2 are limited to the scope expressly granted, and all other rights under all other Intellectual Property Rights owned by or licensed to Sovargen or Kazia are expressly reserved. Where a licence granted by one party to the other party under this clause 2 is for a particular purpose or with respect to a particular product, the granting party retains all of its rights with respect to those Intellectual Property Rights for the purposes not expressly licensed under this Agreement.


10

 

2.7

Delivery and support

 

  (a)

Within 60 days following the Effective Date, Kazia will, at Kazia’s cost, deliver to Sovargen complete copy of the Licenced IP as it exists at the Effective Date.

 

  (b)

If any additional Licenced IP comes into Kazia’s Control during the Term, Kazia will notify Sovargen and provide copies of such Licenced IP within 30 days of such Licenced IP coming into Kazia’s Control.

 

  (c)

Upon Sovargen’s reasonable request, Kazia will provide Sovargen with reasonable technical assistance in connection with the application of the Licenced IP in the Development of the Product, at Sovargen’s cost.

 

3.

Governance

 

3.1

Alliance Managers

 

  (a)

Within 30 days after the Effective Date, each party must appoint (and notify the other party of the identity of) a representative to act as its alliance manager under this Agreement (Alliance Manager) who:

 

  (i)

is fluent in English; and

 

  (ii)

has appropriate qualifications and experience (including a general understanding of pharmaceutical development, manufacture and commercialisation issues).

 

  (b)

The Alliance Managers will serve as the primary contact points between the parties regarding the activities contemplated by this Agreement and will facilitate the flow of information and otherwise promote communication, coordination and collaboration between the parties.

 

  (c)

Each party may replace its Alliance Manager by written notice to the other party.

 

  (d)

The Alliance Managers must meet (Alliance Manager Meeting) at least once each 6 months during the Term to:

 

  (i)

monitor, review and record the progress of any Development of the Compound and the Product, and any Commercialisation of the Product, by Sovargen in the Field in the Territory;

 

  (ii)

identify and address issues involving the Development of the Compound and the Product, or the Commercialisation of the Product, in the Field in the Territory;

 

  (iii)

review filings to be submitted to Regulatory Authorities in the Territory and monitor the submission of such Regulatory Approvals;

 

  (iv)

serve as a general information sharing forum for keeping the parties informed of Development, Manufacturing and Commercialisation activities being conducted by Sovargen, its Affiliates and its sub-licensees under this Agreement;

 

  (v)

consider whether Sovargen has used Commercially Reasonable Efforts to achieve the Performance Milestone; and

 

  (vi)

discuss any other matters relating to the activities conducted under or in relation to this Agreement.

 

3.2

Reporting

 

  (a)

Sovargen must provide to Kazia a report within 60 days after the end of each calendar year during the period commencing on the Effective Date and ending on the Launch Date, which outlines:

 

  (i)

the Development and the Manufacturing of the Compound and the Product in the Field in the Territory it has undertaken during the preceding calendar year;


11

 

  (ii)

the Development Milestone Events that have been satisfied, and the efforts taken by Sovargen to satisfy outstanding Development Milestone Events, the preceding calendar year; and

 

  (iii)

Sovargen’s plans for the Development and Manufacture of the Compound and the Product, and the Commercialisation of the Product, in the following calendar year.

 

  (b)

The parties will review and discuss the report issued under clause 3.2(a) at the next meeting of the Alliance Managers.

 

4.

Development, Manufacture and Commercialisation

 

4.1

General obligations

 

  (a)

Subject to the terms and conditions of this Agreement, Sovargen will be solely responsible for the Development, Manufacture, of the Compound and the Product, and the Commercialisation of the Product, in the Field in Territory, at Sovargen’s own cost and expense.

 

  (b)

Sovargen must use Commercially Reasonable Efforts to maximise the value from the Compound in the Field in the Territory by developing the Product for filing with, and to obtain Regulatory Approvals from, Regulatory Authorities in the Territory to permit Sovargen to Commercialise the Product in the Field in the Territory.

 

  (c)

Without limiting clause 4.1(b), Sovargen must use Commercially Reasonable Efforts to ensure the first patient is dosed with a Product as part of a clinical trial of the Product in the Field in the Territory by no later than the date that is 18 months after the Effective Date (the Performance Milestone).

 

  (d)

At least 10 Business Days prior to an Alliance Manager Meeting, Sovargen must provide to Kazia a report setting out:

 

  (i)

the steps it has taken since the Effective Date to maximise the value from the Compound in the Field in the Territory;

 

  (ii)

the steps it has taken since the Effective Date to achieve the Performance Milestone, including a description of the specific steps it has taken since the last Alliance Management Meeting; and

 

  (iii)

any other information which is relevant to the assessment of whether it has used Commercially Reasonable Efforts to achieve the Performance Milestone,

(the Performance Milestone Report).

 

  (e)

If, based on the Performance Milestone Report, Kazia considers that Sovargen has failed to use Commercially Reasonable Efforts to meet the Performance Milestone, at the Alliance Manager Meeting, the parties must, acting reasonably and in good faith, agree:

 

  (i)

any variations (including an extension of time) to the Performance Milestone; and / or

 

  (ii)

a remediation plan so that Sovargen may take steps to achieve the Performance Milestone.

 

  (f)

Where clause 4.1(e) applies, if:

 

  (i)

the parties are unable to agree on variation to the Performance Milestone or a remediation plan (as is applicable) within 10 Business Days of the Alliance Manager Meeting; or

 

  (ii)

the parties are able to agree on variation to the Performance Milestone or a remediation plan (as is applicable) within 10 Business Days of the Alliance Manager Meeting, but Sovargen fails to satisfy the revised Performance Milestone or does not comply with the agreed remediation plan (as is applicable),

 

   

then Kazia may, upon 60 days’ prior written notice, terminate the Agreement, in whole or on a country by country basis, by providing written notice to Sovargen. However, Sovargen shall be granted at least three opportunities to revise the remediation plan, and following each revision, the parties shall engage in good faith discussions regarding the revised plan before Kazia may consider terminating the Agreement.


12

 

4.2

Clinical trials

 

  (a)

Sovargen (either itself or through its Affiliates or sub-licensees) may, at its own cost and expense, conduct pre-clinical studies and clinical trials of the Compound and the Product in the Field in the Territory provided that Sovargen:

 

  (i)

provides Kazia with a draft of any proposed protocol or material protocol amendments relating to the proposed GLP toxicology study or clinical trial (as the case may be) of the Compound or the Product in the Field in the Territory; and

 

  (ii)

considers, in good faith, any comments provided by Kazia in relation to a proposed protocol or material protocol amendment within 14 days of Kazia first receiving that protocol or material protocol amendment (as is applicable) for review.

 

  (b)

Sovargen must ensure that all pre-clinical studies and clinical trials carried out in the Territory with respect to the Compound or the Product in the Field comply with all applicable Laws, Regulatory Approvals and regulatory requirements.

 

  (c)

Kazia must, at Sovargen’s request, supply the Kazia Product to Sovargen for the sole purpose of Sovargen conducting pre-clinical studies and clinical trials relevant to the Compound and the Product in the Field in the Territory in accordance with this Agreement and the Supply Agreement agreed by the parties in accordance with clause 4.5(a).

 

  (d)

Sovargen must:

 

  (i)

not use the Kazia Product other than to conduct pre-clinical studies and clinical trials related to the Development of the Compound and the Product in the Field in the Territory in accordance with this Agreement; and

 

  (ii)

not otherwise develop, market, distribute or sell the Kazia Product.

 

4.3

Data sharing

 

  (a)

Sovargen must:

 

  (i)

keep Kazia informed of the Development activities conducted by it or on its behalf (including by its Affiliates and sub-licensees) with respect to the Compound and the Products; and

 

  (ii)

subject to applicable Laws, provide Kazia with copies of all data and results, including pre-clinical data, clinical reports and reasonable supporting documentation (such as protocols and data analysis plans) relevant to the Development of the Compound and the Products in the Field generated by or on its behalf and all information pertaining to the Regulatory Approval obtained for, or applied for, the Products.

 

  (b)

Kazia will have the right to use and reference all information, data, documentation and results provided by Sovargen, including clinical and non-clinical findings, without additional consideration, including for the purpose of seeking Regulatory Approval of the Product in the Field outside the Territory.

 

  (c)

Kazia must:

 

  (i)

keep Sovargen informed of the Development activities conducted by or on its behalf (including its Affiliates and Third Parties) for the Compound and Product that are relevant to the Development activities conducted by or on behalf of Sovargen; and


13

 

  (ii)

subject to applicable Laws, must provide Sovargen with copies of data and results, including pre-clinical data, clinical reports and reasonable supporting documentation (such as protocols and data analysis plans) relevant to the Development of the Compound or Product generated by or on its behalf.

 

  (d)

Sovargen will have the right to use and reference all information, data, documentation and results provided by Kazia, including clinical and non-clinical findings without additional consideration, including for the purpose of seeking Regulatory Approvals of the Product in the Field in the Territory.

 

4.4

Regulatory

 

  (a)

Subject to the remainder of this clause 4.4, Sovargen (either itself or through its Affiliates or sub-licensees) must, at its own cost and expense:

 

  (i)

apply for and maintain all Regulatory Approvals of the Product in the Field in the Territory; and

 

  (ii)

be responsible for payment of all fees and charges payable with respect to each application for each Regulatory Approval and any transfer, variation, maintenance or renewal of each Regulatory Approval.

 

  (b)

Sovargen will be responsible for the preparation of all Regulatory Materials and all communications and interactions with Regulatory Authorities with respect to the Product in the Field in the Territory, both prior to and subsequent to Regulatory Approval. Sovargen (or its Affiliate or sub-licensee) must file all required regulatory dossiers to obtain (and maintain) Regulatory Approval of the Product in the Field in the Territory and will be the holder of such Regulatory Approvals in the Territory.

 

  (c)

Unless otherwise agreed by the parties in writing, prior to responding to, or submitting, any material communication to any Regulatory Authority with respect to the Product in the Territory, Sovargen shall submit such response or communication to Kazia for review and shall consider in good faith any comments provided by Kazia.

 

  (d)

Kazia (and its collaborators and contractors) will have the right to submit Regulatory Materials, communicate with Regulatory Authorities, and hold Regulatory Approvals with respect to the Product:

 

  (i)

outside the Territory and within the Field, provided that Kazia first:

 

  (A)

provides Sovargen with a draft of the proposed submission or communication in relation to the Regulatory Materials or Regulatory Approvals with respect to the Product; and

 

  (B)

considers, in good faith, any comments provided by Sovargen in relation to the proposed submission or communication within 14 days of Sovargen first receiving that proposed submission or communication (as is applicable) for review.

 

  (e)

Each party must:

 

  (i)

keep the other party reasonably informed on the regulatory activities conducted by or on behalf of such party (including its Affiliates, licensees and sub-licensees) for the Product;

 

  (ii)

provide the other party with copies of all Regulatory Materials directly relevant to the Development of the Compound or the Product, or the Commercialization of the Product, in the Field submitted to or received from Government Agencies.

 

  (f)

Each party hereby grants to the other party a right of reference to all Regulatory Materials filed by or on behalf of such party for the Product, which right of reference the other party may use for the purpose of seeking, obtaining and maintaining Regulatory Approvals for the Product in the Field in such other party’s territory.


14

 

  (g)

Without limiting clauses 4.4(e) and 4.4(f), subject to availability and adequate resourcing, Kazia will provide reasonable assistance to Sovargen, at Sovargen’s cost, in relation to the regulatory activities conducted by Sovargen in relation to the Product.

 

4.5

Supply and Manufacture

 

  (a)

Promptly following the Effective Date, but in no event later than the 90 days after the Effective Date, Kazia and Sovargen will, acting reasonably and in good faith, to agree the terms of, and enter into, a supply agreement which sets out the terms on which Kazia will supply the Compound and Kazia Product to Sovargen in accordance with this Agreement (Supply Agreement).

 

  (b)

Kazia will, or will procure a Third Party contract manufacturer to, Manufacture and supply amounts of the Compound and Kazia Product requested by Sovargen (for the purposes of Development of the Compound and Product in the Field in the Territory) in accordance with the this Agreement and the Supply Agreement agreed by the parties in accordance with clause 4.5(a) and as agreed to by Kazia at a price equal to Kazia’s actual cost of the Manufacture and supply of such Compound or Kazia Product (as is applicable) plus a [***] mark up.

 

  (c)

Sovargen must not purchase or obtain the Compound or Kazia Product other than in accordance with clause 4.5(a).

 

  (d)

Sovargen may Manufacture, or have Manufactured, the Product or the Compound for Development and Commercialisation in the Field in the Territory either itself or through a Third Party contract manufacturer, provided that such contract manufacturer is located in the Territory.

 

  (e)

Upon Sovargen’s reasonable request, Kazia will:

 

  (i)

if it has not already done so, make available to Sovargen all Licenced Know-How related to the Manufacture of the Compound and the Product; and

 

  (ii)

subject to availability and adequate resourcing, provide Sovargen, at Sovargen’s cost, with any reasonable technical assistance to the extent necessary to enable Sovargen to Manufacture the Compound and the Product in the Field in the Territory.

 

4.6

Commercialisation

 

  (a)

Subject to clause 4.6(b), Sovargen (either itself or through its Affiliates and sub-licensees) will be responsible for all aspects of the Commercialisation of the Product in the Field in the Territory, at Sovargen’s own cost, including:

 

  (i)

developing and executing a commercial launch and pre-launch plan;

 

  (ii)

negotiating with applicable Government Agencies regarding the price and reimbursement status of the Product in the Field;

 

  (iii)

marketing and promotion;

 

  (iv)

booking sales and distribution and performance of related services;

 

  (v)

handling all aspects of order processing, invoicing and collection, inventory and receivables;

 

  (vi)

providing customer support, including handling medical queries, and performing other related functions; and

 

  (vii)

conforming its practices and procedures to applicable Laws relating to the marketing, detailing and promotion of the Product in the Field in the Territory.

 

  (b)

Sovargen must only market, distribute and sell the Product in the Field in the Territory. Sovargen (either itself or through its Affiliates or sub-licensees) must not sell any Product to parties where it knows or should know, or where it reasonably suspects, that the party may seek to sell the Product outside of the Territory and / or outside the Field.


15

 

4.7

Pharmacovigilance

 

 

Promptly following the Effective Date, but in no event later than the date the first clinical trial of a Product is initiated by Sovargen, its Affiliates or sub-licensees, Kazia and Sovargen will, acting reasonably and in good faith, to agree the terms of, and enter into, a written pharmacovigilance agreement which sets out the parties’ respective obligations with respect to safety and pharmacovigilance procedures for the Product, such as data sharing and exchange, adverse event reporting and prescription events monitoring and to cause its Affiliates and sub-licensees to comply with the same.

 

4.8

Safety concerns

 

  (a)

If either party:

 

  (i)

becomes aware of any health or safety concern with respect to the Product or any product incorporating the Licenced IP, including any adverse event; or

 

  (ii)

receives any correspondence from any Government Agency with respect to any concerns, investigations, recalls, audits or similar with respect to the Product or any product incorporating the Licenced IP,

that party must immediately notify the other of such health or safety concern or correspondence, and the parties must act together in good faith to address such health or safety concern or correspondence.

 

  (b)

Sovargen will, at its costs, be responsible for coordinating any recall or market withdrawal of the Product in the Field in the Territory, provided that:

 

  (i)

it consults with Kazia regarding any such recall or market withdrawal;

 

  (ii)

it provides to Kazia a copy of any communication from, or which Sovargen proposes to provide to, a Government Agency relating to such recall or market withdrawal; and

 

  (iii)

Kazia has the ability to review and comment on any proposed communications Sovargen proposes to send to a Government Agency and Sovargen considers such comments in good faith and acting reasonably.

 

  (c)

Notwithstanding any other provision of this Agreement, Kazia will have an absolute right to take any measures necessary with respect to the Development of the Compound or the Product, or the Manufacture and / or Commercialisation of the Product, where it considers, acting reasonably and in good faith, that taking such action with respect to the Compound or that particular Product (having regard to the dosage and indication of that Product) is necessary to directly ensure patient safety as raised by appropriate Regulatory Authorities.

 

5.

Milestone payments

 

5.1

Upfront payment

 

 

Within 15 Business Day following the Effective Date and subject to receipt of an invoice issued by Kazia, Sovargen must pay to Kazia a one-time, non-refundable upfront payment of USD$1,500,000.

 

5.2

Development Milestone payments

 

  (a)

Sovargen must use Commercially Reasonable Efforts to satisfy each Development Milestone Event set out in Schedule 3.

 

  (b)

Sovargen must give Kazia written notice of the satisfaction of each Development Milestone Event within 5 Business Days of such Development Milestone Event being satisfied.


16

 

  (c)

Subject to clause 7 and the issue of a valid invoice, Sovargen must pay to Kazia the Development Milestone Amount within 45 days of Sovargen satisfying the relevant Development Milestone Event.

 

  (d)

Each Development Milestone Amount will only be paid by Sovargen to Kazia once.

 

5.3

Commercial milestone payments

 

  (a)

If Sovargen sub-licences any rights and licences granted in this Agreement to a sub-licensee(s) to allow the sub-licensee(s) to Commercialise the Product in the Field in (any or all of) the Territory, Sovargen must, within 30 days after the end of each calendar quarter in which the sub-licensee(s) records Net Sales of the Product and subject to receiving a valid invoice from Kazia, pay to Kazia an amount equal to [***] of the total commercial milestone payments received by Sovargen in consideration of each such sub-licence granted by Sovargen to its sub-licensee(s) during the previous calendar quarter.

 

  (b)

If Sovargen does not sub-license any rights and licences granted in this Agreement to a sub-licensee(s) with respect to the entire Territory and, instead, Commercialises the Product in the Field in (any or all) the Territory itself, the parties must, acting reasonably and in good faith, use best endeavours to agree, prior to the First Commercial Sale of the Product or as soon as practicable thereafter:

 

  (i)

commercial milestones that Sovargen must use Commercially Reasonable Efforts to satisfy; and

 

  (ii)

the amount Sovargen must pay to Kazia when Sovargen satisfies each such commercial milestone and the terms of such payment.

 

6.

Royalty payments

 

6.1

Royalty Term

 

 

Sovargen’s obligation to pay royalties with respect to a Product in the Field in each country in the Territory pursuant to this clause 5.3 commences on the date of the First Commercial Sale of that Product in the relevant country and ends, with respect to that country, upon the later of:

 

  (a)

the expiration or loss of the last to expire or be lost Valid Claim that claims the composition matter of the Compound in the Product or the Product itself in the Field in the relevant country.

 

  (b)

10 years after the First Commercial Sale of that Product in the relevant country,

 

 

(the Royalty Term).

 

6.2

Royalty conditions

 

 

The royalties payable under this clause 6 are subject to the following conditions:

 

  (a)

only 1 royalty will be due with respect to each unit of Product, without regard to whether there is more than 1 Valid Claim or Licenced Patent claiming such Product; and

 

  (b)

no royalties will be due upon the sale or other transfer of the Product among Sovargen, its Affiliates and sub-licensees, but in such cases the royalty will be due and calculated upon Sovargen’s, its Affiliate’s or sub-licensee’s Net Sales of Product to the first Third Party.

 

6.3

Royalty Report

 

  (a)

Within 30 days after the end of each calendar quarter, commencing from the First Commercial Sale of a Product in the Territory, Sovargen will provide Kazia with a royalty report that contains the following information for the applicable calendar quarter (to date if not yet a full calendar year), on a Product-by-Product and country-by-country basis:

 

  (i)

the number of units of each Product sold;


17

 

  (ii)

the amount of gross sales of the Product;

 

  (iii)

a calculation of Net Sales of the Product;

 

  (iv)

if Sovargen sub-licences any rights and licences granted in this Agreement to a sub-licensee(s) to allow the sub-licensee(s) to Commercialise the Product in the Field in the Territory:

 

  (A)

all royalty payments in relation to Net Sales of the Product which were received by Sovargen in consideration of each such sub-licence; and

 

  (B)

all commercial milestone payments received by Sovargen in consideration of each such sub-licence granted by Sovargen to its sub-licensee(s);

 

  (v)

a calculation of the royalty payment due to Kazia under this Agreement based on such Net Sales;

 

  (vi)

a calculation of the commercial milestones payments due to Kazia under this Agreement;

 

  (vii)

the exchange rate used to convert Net Sales and any commercial milestone payments from the currency in which such payments were earned or received to USD based on clause 8.1(b);

 

  (viii)

the aggregate annual Net Sales for the period,

 

   

(the Royalty Report).

 

  (b)

Sovargen must provide with the Royalty Report evidence, to the reasonable satisfaction of Kazia, to support all amounts set out in the Royalty Report.

 

6.4

Payment

 

 

Subject to the issue of a valid invoice by Kazia and to clause 6.5, Sovargen must make quarterly non-refundable royalty payments to Kazia within 45 days after the issue of a valid invoice by Kazia with respect to the Net Sales of the Product in the Field sold in the Territory, calculated as follows:

 

  (a)

if Sovargen sub-licences any rights and licences granted in this Agreement to a sub-licensee(s) to allow the sub-licensee(s) to Commercialise the Product in (all or any of) the Field in the Territory, an amount equal to [***] of the royalty payments received by Sovargen from its sub-licensee(s) in consideration of the sub-licence granted to its sub-licensee(s); or

 

  (b)

if Sovargen does not sub-licence the rights and licences granted in this Agreement to a sub-licensee(s) for the entire Territory and Commercialises the Product in the Field in (all or any of) the Territory itself, an amount equal to [***] (this amount shall be equal to [***] if the Territory is the Republic of Korea) of the aggregated Net Sales of the Product sold by Sovargen during the applicable calendar quarter. However, in case when there is no Valid Claim in the Licensed Patents that claims the composition of matter of the Compound contained in such Product in such region, then the royalty rate applicable to the Net Sales of such Product in such region during such time shall be reduced by [***] (or reduced by [***] if the Territory is the Republic of Korea).

 

6.5

Dispute

 

  (a)

Within 10 Business Days after the date on which the Royalty Report is given to Kazia (Review Period), Kazia may, acting reasonably and in good faith, make an enquiry to Sovargen regarding any aspect of the Royalty Report (Royalty Query).

 

  (b)

If at the end of the Review Period, Kazia has not made any Royalty Query, all amounts set out in the Royalty Report will be taken to be final and binding on the parties and payment must be made in accordance with clause 6.4.

 

  (c)

If a Royalty Query is made within the Review Period, then:


18

 

  (i)

Sovargen must properly respond to such Royalty Query, including (if applicable) providing evidence to support the amounts set out in the Royalty Report; and

 

  (ii)

Kazia and Sovargen must use their reasonable endeavours to resolve any outstanding aspects of the Royalty Query.

 

  (d)

If the Royalty Query has not been resolved within 45 days after the Royalty Query is made, then either party may refer the Royalty Query to an Expert in accordance with, and for determination in accordance with, Schedule 4.

 

  (e)

If there is a Royalty Query that is not resolved by the parties nor referred to an Expert in accordance with clause 6.5(d), all amounts set out in the Royalty Report are will be taken to be final and binding on the parties, the Royalty Query will be taken to be resolved and payment must be made in accordance with clause 6.4.

 

  (f)

If there is a Royalty Query that is resolved or otherwise agreed by the parties, or determined by an Expert in accordance with Schedule 4, Sovargen must pay to Kazia the royalty amounts due in accordance with clause 6.4 based on the Royalty Report amounts agreed between the parties or determined by the Expert (as applicable) within 10 Business Days of such resolution or determination.

 

7.

Paediatric review vouchers

 

  (a)

Sovargen must notify Kazia in writing if the FDA awards Sovargen a rare paediatric disease review voucher in relation to the Product (Product PDV) at any time during the Term.

 

  (b)

If Sovargen sells a Product PDV at any time during the Term, Sovargen must:

 

  (i)

immediately notify Kazia in writing of the sale and the value of the Product PDV received by Sovargen; and

 

  (ii)

pay to Kazia an amount equal to [***] of the value of the Product PDV received by Sovargen within 45 days after receipt of an invoice issued by Kazia.

 

  (c)

If Sovargen does not sell the Product PDV during the Term, promptly following the expiration or early termination of this Agreement, Sovargen must pay to Kazia an amount equal to [***] of the average sale value of the 3 most recently sold rare paediatric disease review vouchers that:

 

  (i)

were sold by Third Parties; and

 

  (ii)

had a sale value which was published publicly.

 

8.

Manner of making payments

 

8.1

Making payments

 

  (a)

All payments due to Kazia under this Agreement must be paid by electronic funds transfer to an account nominated by Kazia from time to time.

 

  (b)

The rate of exchange to be used in calculating the amount of currency equivalent in USD will be made at the average of the closing exchange rates reported by KB Kookmin Bank in Republic of Korea for the first, middle and last Business Days of the applicable reporting period for the payment due.

 

8.2

Late payments

 

 

If Kazia does not receive payment of any sum due to it on or before the due date, interest will accrue on the sum due from the due date until the date of payment, calculated over the period between the due date and the date of payment at a rate of 2 percentage points over the 6 month London Inter-bank Offered Rate.

 

8.3

Payment obligations

 

 

Sovargen will be solely responsible for the payment of royalty, milestone and other payments due under this Agreement on account of Sovargen’s, its Affiliates’ and its sub- licensees’ Development and Manufacture of the Compound and the Product, and the Commercialisation of the Product, in the Field in the Territory.


19

 

8.4

Taxes

 

  (a)

Each party will be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the parties under this Agreement. For clarity, all payment amounts in clauses 5 and 6 are on a pre-tax basis.

 

  (b)

The parties agree to cooperate with one another and use reasonable efforts to, acting properly, reduce tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made under this Agreement.

 

  (c)

To the extent Sovargen is required to deduct and withhold taxes on any payment to Kazia, Sovargen will deduct those taxes from the remittable payment, pay the taxes to the proper tax authority in a timely manner, and promptly send proof of payment to Kazia. Kazia will provide Sovargen any tax forms that may be reasonably necessary in order for Sovargen to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. At the request and expense of Kazia, Sovargen will provide reasonable assistance to enable the recovery, to the extent permitted by Law, of withholding taxes or similar obligations resulting from payments made under this Agreement.

 

9.

Records and audit

 

  (a)

During the Term and for a period 7 years thereafter or such longer period as may be required by any applicable Law or Government Agency in respect of any activity under this Agreement, Sovargen must:

 

  (i)

keep full, true and accurate records of its compliance with its obligations under this Agreement and its and its Affiliates’ and sub-licensees’ sales, transfers and other dispositions of the Product, including the particulars of Net Sales and the calculation of royalties under this Agreement; and

 

  (ii)

procure its Affiliates and sub-licensees to keep full, true and accurate records of sales, transfers and other dispositions of the Product, including the particulars of Net Sales and the calculation of royalties under this Agreement.

 

  (b)

At any time during the Term and for a period of 7 years following the Term, Kazia may appoint an independent third party (Auditor) to inspect the relevant records of:

 

  (i)

Sovargen to verify Sovargen’s compliance with its obligation under this Agreement and / or any reports, statements or invoices provided, or payments made, by Sovargen under or in connection with this Agreement; or

 

  (ii)

Sovargen’s Affiliates or sub-licensees to verify that the amount of any royalties paid under this Agreement was correctly determined.

 

  (c)

Sovargen must, and must procure that its Affiliates and sub-licensees, permit the Auditor to access and inspect all records kept in accordance with this Agreement, provided that:

 

  (i)

any Auditor may only access the relevant party’s records, a maximum of 2 times per year, unless:

 

  (A)

Kazia has reasonable grounds to suspect that an act or omission by the relevant party has led to or resulted in a breach of this Agreement;

 

  (B)

a prior inspection in that calendar year determined an error by the relevant party resulting in underpayment to Kazia of greater than 5% for the audited period; or


20

 

  (C)

Kazia is required to verify payments made under this Agreement as a result of Genentech seeking to conduct an audit in accordance with the terms of the Genentech Agreement;

 

  (ii)

Kazia provides at least 30 Business Days’ notice prior to the date on which it is requesting access for the Auditor;

 

  (iii)

the Auditor only inspects the relevant party’s records during ordinary business hours and does not disrupt the ordinary business of the relevant party while doing so;

 

  (iv)

while inspecting the records, the Auditor complies with:

 

  (A)

all reasonable directions of the relevant party; and

 

  (B)

all applicable policies and procedures of the relevant party, including any occupational health and safety policies and procedures;

 

  (v)

the Auditor executes a reasonable and balanced confidentiality agreement with the relevant party which the relevant party must prepare, or otherwise agrees to be subject to terms governing non-use and non-disclosure of information that the relevant party has agreed, acting reasonably, in writing are acceptable; and

 

  (vi)

subject to clause 9(g), Kazia will pay the costs of any inspection.

 

  (d)

The Auditor will be instructed to provide to Kazia an audit report containing its conclusions regarding the inspection, and, where applicable, specifying whether the amounts paid under the Agreement were correct, and, if incorrect, the amount of any underpayment or overpayment. Kazia may share this audit report with Sovargen at its sole discretion.

 

  (e)

After review of the Auditor’s report:

 

  (i)

if there is an uncontested underpayment by Sovargen for the period in question, then within 30 days of delivery of the Auditor’s report in accordance with clause 9(d), Sovargen will pay to Kazia the full amount of that uncontested underpayment;

 

  (ii)

if there is an uncontested overpayment by Sovargen for the period in question, then within 30 days of delivery of the Auditor’s report in accordance with clause 9(d), Kazia will pay to Sovargen the full amount of that overpayment; and

 

  (iii)

if there is a contested amount, such contested amount will be subject to dispute resolution by an Expert in accordance with Schedule 4. If the Expert determines in accordance with Schedule 4 that:

 

  (A)

the contested amount is an underpayment by Sovargen for the period in question, then within 30 days of the Expert’s determination Sovargen will pay to Kazia the full amount of that underpayment; or

 

  (B)

the contested amount is an overpayment by Sovargen for the period in question, then within 30 days of the Expert’s determination Kazia will provide to Sovargen a credit against future payments (such credit equal to the full amount of that overpayment), or, if Sovargen is not obliged to make any future payments, then Kazia will pay to Sovargen the full amount of that overpayment.

 

  (f)

Where the Auditor’s report reveals that Sovargen is in breach of its obligations under this Agreement, the parties will promptly meet to agree a remediation plan such that any breach by Sovargen may be remedied. In such case, Kazia must provide to Sovargen reasonable evidence of the relevant findings set out in the Auditor’s report.


21

 

  (g)

If:

 

  (i)

the total amount of any underpayment (as agreed to by Sovargen or as determined by the Expert under Schedule 4) exceeds 10% of the amount previously paid by Sovargen for the period the subject of the inspection; or

 

  (ii)

the inspection reveals a material breach by Sovargen of its obligations under this Agreement,

then Sovargen will pay the reasonable costs for the inspection.

 

  (h)

The full amount of any underpayment by Sovargen determined to be payable to Kazia pursuant to this clause 9 will accrue interest calculated in accordance with clause 8.2.

 

10.

Confidentiality

 

10.1

Obligations of confidentiality

 

 

Subject to clauses 10.2 and 10.3, the Receiving Party must:

 

  (a)

keep the Confidential Information confidential and not directly or indirectly disclose, divulge or communicate any Confidential Information to, or otherwise place any Confidential Information at the disposal of, any other person without the prior written approval of the Disclosing Party;

 

  (b)

take all reasonable steps to secure and keep secure all Confidential Information coming into its possession or control;

 

  (c)

only use the Confidential Information for the purposes of performing, and to the extent necessary to perform, its obligations under this Agreement;

 

  (d)

not deliberately memorise, modify, reverse engineer or make copies, notes or records of the Confidential Information for any purpose other than in connection with the performance by the Receiving Party of its obligations under this Agreement; and

 

  (e)

take all reasonable steps to ensure that any person to whom the Receiving Party is permitted to disclose Confidential Information under clause 10.3 complies at all times with the terms of this clause 10 as if that person were a Receiving Party.

 

10.2

Exceptions

 

 

The obligations of confidentiality under clause 10.1 do not apply to:

 

  (a)

any Confidential Information that:

 

  (i)

is disclosed to the Receiving Party by a Third Party entitled to do so, whether before or after the date of this Agreement;

 

  (ii)

was already lawfully in the Receiving Party’s possession when it was given to the Receiving Party and was not otherwise acquired from the Disclosing Party directly or indirectly; or

 

  (iii)

is generally available to the public at the date of this Agreement or subsequently becomes so available other than by reason of a breach of this Agreement; or

 

  (b)

any disclosure of Confidential Information by the Receiving Party that is necessary to comply with any court order or Law if, to the extent practicable and as soon as reasonably possible, the Receiving Party:

 

  (i)

notifies the Disclosing Party of the proposed disclosure;

 

  (ii)

consults with the Disclosing Party as to its content; and

 

  (iii)

uses reasonable endeavours to comply with any reasonable request by the Disclosing Party concerning the proposed disclosure.


22

 

10.3

Authorised disclosure

 

 

A Receiving Party may disclose Confidential Information to any Affiliate, employee, agent, contractor, officer, professional adviser, banker, auditor or other consultant of the Receiving Party (each a Recipient) only if the disclosure is made to the Recipient strictly on a “need to know basis” and, prior to the disclosure:

 

  (a)

the Receiving Party notifies the Recipient of the confidential nature of the Confidential Information to be disclosed;

 

  (b)

the Recipient undertakes to the Receiving Party (for the benefit of the Disclosing Party) to be bound by the obligations in this clause 10 as if the Recipient were a Receiving Party in relation to the Confidential Information to be disclosed to the Recipient; and

 

  (c)

if requested to do so by the Disclosing Party, the Recipient signs an undertaking or deed in a form acceptable to the Disclosing Party acting reasonably (and for the benefit of the Disclosing Party) agreeing to be bound by the obligations in this clause 10 as if it were a Receiving Party in relation to the Confidential Information to be disclosed to the Recipient.

 

10.4

Return or destruction of confidential information

 

  (a)

Immediately on the written request of the Disclosing Party or on the termination of this Agreement for any reason, a Receiving Party must:

 

  (i)

cease the use of all Confidential Information of or relating to the Disclosing Party (or any Affiliate of the Disclosing Party);

 

  (ii)

deliver to the Disclosing Party all documents and other materials in its possession or control containing, recording or constituting that Confidential Information or, at the option of the Disclosing Party, destroy, and certify to the Disclosing Party that it has destroyed, those documents and materials; and

 

  (iii)

for Confidential Information stored electronically, permanently delete that Confidential Information from all electronic media on which it is stored, so that it cannot be restored.

 

  (b)

The Receiving Party will not be required to delete or destroy any electronic back-up tapes or other electronic back-up files that have been created solely by its automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with its standard archiving and back-up procedures, provided that the confidentiality obligations of this clause 10 will continue to apply to any retained Confidential Information.

 

10.5

Liability for breach by recipient

 

 

The Receiving Party is liable for any breach of this clause 10 by a Recipient as if the Recipient was a Receiving Party in relation to the Confidential Information disclosed to the Recipient.

 

10.6

Public announcements

 

  (a)

Notwithstanding any other provision of this Agreement, promptly after the Effective Date:

 

  (i)

Kazia will issue the press release announcing this Agreement set out in Part A of Schedule 5; and

 

  (ii)

Sovargen will issue the press release announcing this Agreement set out in Part B of Schedule 5.

 

  (b)

A party must not make, or authorise or cause to be made, any public announcement relating to the negotiations between the parties or the subject matter of this Agreement unless:

 

  (i)

it has the prior written consent of each other party; or


23

 

  (ii)

it is required to do so by Law.

 

  (c)

If a party is required to make a public announcement under clause 10.6(a), it must before doing so, to the extent practicable and as soon as reasonably possible:

 

  (i)

notify the other party of the proposed announcement;

 

  (ii)

consult with the other party as to its content; and

 

  (iii)

use reasonable endeavours to consider any reasonable request by any other party concerning the proposed announcement.

 

10.7

Publications

 

  (a)

Sovargen may publish materials relating to the Compound or the Product in the Field, provided that Sovargen:

 

  (i)

provides Kazia with a draft of any proposed publication relating to the Compound or Product at least 30 days prior to its intended submission for publication;

 

  (ii)

upon Kazia’s request, removes any and all of Kazia’s Confidential Information from the proposed publication, and delays the submission for a period up to 90 days to allow time for the preparation and filing of a Patent application directed to any Intellectual Property Rights disclosed in such publication;

 

  (iii)

considers, in good faith, any comments provided by Kazia in relation to the proposed submission within 14 days of Kazia first receiving that submission for review; and

 

  (iv)

provides Kazia a copy of the manuscript at the time of the submission.

 

  (b)

Kazia will keep Sovargen informed on any scientific publication relating to the Compound and Product, of which a Kazia employee is an author, and will provide Sovargen with a draft of any such proposed publication for review at least 30 days prior to its intended submission for publication. Kazia will consider Sovargen’s comments in good faith and will not include any Confidential Information of Sovargen in its publication, but Sovargen will not have the right to approve Kazia’s publication.

 

10.8

Equitable relief

 

 

Each party acknowledges agrees that:

 

  (a)

a breach of this clause 10 cannot reasonably or adequately be compensated in damages in an action at law and that such a breach will cause the other party irreparable injury and damage; and

 

  (b)

the other will be entitled, in addition to any other remedies it may have under this Agreement or otherwise, to preliminary and permanent injunctive and other equitable relief to prevent or curtail any breach of the obligations relating to Confidential Information set out in this Agreement.

 

11.

Prosecution, enforcement and defence of Intellectual Property Rights

 

11.1

Prosecution of Licenced Patents

 

  (a)

As between the parties, Kazia will have the first right to file, prosecute and maintain all Patents within the Licenced Patents throughout the world, at Kazia’s own cost and expense.

 

  (b)

Kazia will consult with Sovargen and keep Sovargen reasonably informed of the status of the Licenced Patents in the Territory, and will promptly provide Sovargen with all material correspondence received from any patent authority in the Territory in connection with the same.

 

  (c)

Kazia will notify Sovargen of any decision to cease prosecution or maintenance of any Licenced Patents in the Territory at least 30 days prior to any filing or payment due date, or any other due date that requires action, in connection with such Licenced Patent.


24

 

  (d)

Each party will provide the other party all reasonable assistance and cooperation in the Patent prosecution efforts under this clause 11, including providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution.

 

11.2

Notification of Infringements and Proceedings

 

 

Each party must immediately notify the other party of:

 

  (a)

any infringement or threatened infringement or any unauthorized use of or application (Infringement); or

 

  (b)

any issue, claim, demand, threat, notice of proceedings or causes of action (whether contingent, accrued or otherwise) (Proceedings),

it becomes aware of relating to any Patent within the Licenced IP in the Territory.

 

11.3

Enforcement of Licenced Patents

 

  (a)

As between the parties, Kazia will have the first right, in its sole discretion and at its sole expense, to take action in relation to an Infringement or Proceedings relating to any Patent within the Licenced Patents.

 

  (b)

In the event that Kazia declines within 6 months of becoming aware of or notification of an Infringement or Proceedings relating to a Patent within the Licenced Patents to either:

 

  (i)

take action in relation to the Infringement or Proceedings; or

 

  (ii)

initiate and thereafter maintain legal proceedings with respect to the Infringement or Proceedings,

 

   

Sovargen, in its sole discretion, may initiate such proceedings at its sole expense.

 

  (c)

At the request and expense of the party bringing the action under clause 11.3(a) or 11.3(b), the other party will provide reasonable assistance in connection with the action, including by executing reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required. In connection with any such proceeding, the party bringing the action under clause 11.3(a) or 11.3(b) must keep the other party reasonably informed on the status of such action.

 

  (d)

Where Sovargen takes action in connection with an Infringement or Proceedings, it will not enter into any settlement admitting the invalidity of, or otherwise impairing Kazia’s rights in, the Licenced Patents without the prior written consent of Kazia.

 

  (e)

Any settlements, damages or monetary awards recovered by a party as the result of legal proceedings taken in relation to an Infringement or Proceedings in accordance with this Agreement will be allocated solely to the party which took action in relation to that Infringement or Proceedings.

 

12.

Trademarks

 

  (a)

Sovargen must not use (and does not have any right to use) any trademark or trade name Controlled by Kazia or its licensees or used by Kazia or its licensees.

 

  (b)

Sovargen will, at its own cost and expense, have the right to brand the Product for use in the Field in connection with its Commercialisation in the Territory using Sovargen related trademarks and any other trademarks and trade names Sovargen determines appropriate for the Products, which may vary by country or within a country in the Territory (Product Marks).

 

  (c)

Sovargen will own all rights in the Product Marks, and all goodwill in the Product Marks will accrue to Sovargen. Sovargen will register, maintain and enforce, at its own cost and expense, the Product Marks in the Territory as Sovargen determines reasonably necessary.


25

 

13.

Representations and warranties

 

13.1

Mutual warranties

 

 

Each party represents and warrants that, as at the date of execution of this Agreement and on each day during the Term:

 

  (a)

it is registered and validly existing under the Laws of the jurisdiction in which it was incorporated;

 

  (b)

it has full legal capacity and power to enter into this Agreement and to carry out the transactions that this Agreement contemplates;

 

  (c)

all corporate action has been taken that is necessary or desirable to authorise its entry into this Agreement and its carrying out of the transactions that this Agreement contemplates;

 

  (d)

it holds each approval that is necessary or desirable to:

 

  (i)

execute this Agreement and to carry out the transactions that this Agreement contemplates; and

 

  (ii)

ensure that this Agreement is legal, valid, binding and admissible in evidence,

 

   

and it is complying with any conditions to which any of these approvals is subject;

 

  (e)

this Agreement constitutes legal, valid and binding obligations, enforceable against it in accordance with its terms, subject to any necessary stamping or registration;

 

  (f)

neither its execution of this Agreement, nor the carrying out by it of the transactions that this Agreement contemplates, does or will:

 

  (i)

contravene any Law to which it or any of its property is subject or any order of any Government Agency that is binding on it or any of its property;

 

  (ii)

contravene any undertaking or instrument binding on it or any of its property; or

 

  (iii)

contravene its constitution;

 

  (g)

to the best of its knowledge, there are no actions, claims, proceedings or investigations pending or threatened against it or by, against or before any person that may have a material effect on the subject matter of this Agreement;

 

  (h)

it is not the subject of an Insolvency Event;

 

  (i)

it is not entering into this Agreement as trustee of any trust or settlement;

 

  (j)

it is not a party to any agreement that would materially prevent it from performing its obligations under this Agreement;

 

  (k)

it has the right to disclose its Confidential Information to the other party and to authorise the Receiving Party of that Confidential Information to use the Confidential Information as permitted by this Agreement; and

 

  (l)

to the best of its knowledge the use of its Confidential Information as permitted by this Agreement does not breach the Intellectual Property Rights of any other person.

 

13.2

Additional Sovargen warranties

 

 

Sovargen represents and warrants to Kazia, as at the date of execution of this Agreement and on each day during the Term, that it will:

 

  (a)

hold the necessary Regulatory Approvals to perform its obligations under this Agreement; and

 

  (b)

comply with all applicable Laws, including those related to Developing and Manufacturing the Compound and the Product, and Commercialising the Product, in the Field.


26

 

13.3

Additional Kazia warranties

 

 

Kazia represents and warrants to Sovargen, as at the date of execution of this Agreement and on each day during the Term, that:

 

  (a)

Kazia is the sole owner of the Licensed IP (other than Licensed IP that is in-licensed by Kazia from Genentech under the Genentech Agreement), free and clear of all liens, and Kazia has the right to grant to Sovargen the rights and licenses under the Licensed IP as purported to be granted hereunder;

 

  (b)

Kazia has not granted any rights in the Licenced IP that are inconsistent with the rights granted to Sovargen under this Agreement;

 

  (c)

except for the Genentech Agreement, there is no agreement between Kazia or its Affiliates and any Third Party pursuant to which Kazia or its Affiliates obtained any right or licence to the Compound or Product or any Intellectual Property Rights related to the Compound or Product;

 

  (d)

to the best of its knowledge, Kazia is not aware of any infringement or misappropriation of any Licenced IP by any Third Party; and

 

  (e)

to the knowledge of Kazia and its Affiliates, there is no pending or alleged or threatened, re-examination, opposition, interference or litigation, or any written communication alleging that any Licensed Patent is invalid or unenforceable anywhere in the world.

 

13.4

Exclusions

 

  (a)

Subject to the express warranties granted in clause 13.3, nothing in this Agreement is or will be construed as:

 

  (i)

a warranty or representation by Kazia as to the validity or scope of any claim or Patents within the Licenced Patents; and

 

  (ii)

a grant by Kazia, whether by implication, estoppel, or otherwise, of any licenses or rights other than that expressly granted under this Agreement.

 

  (b)

Both parties understand that the Compound and Product are the subject of ongoing research and development and neither party can assure that any Product can be successfully Developed or Commercialised.

 

13.5

Reliance on representations and warranties

 

 

Each party acknowledges that the other party has executed this Agreement and agreed to take part in the transactions contemplated by this Agreement in reliance on the representations and warranties that are made in this clause 13.

 

14.

Liability

 

14.1

Indemnification by Kazia

 

 

Kazia indemnifies and must keep indemnified Sovargen, it Affiliates and their respective officers, directors, agents and employees (Sovargen Indemnitees) against all Claims that may be brought against a Sovargen Indemnitee or which a Sovargen Indemnitee may pay, sustain or incur as a result of any one or more of the following:

 

  (a)

gross negligence or wilful misconduct or material failure to comply with applicable Laws by Kazia; or

 

  (b)

any breach by Kazia of the representations or warranties under clauses 13.1 or 13.3,

 

 

except, in each case, to the extent such Claim arises from any act or omission of a Sovargen Indemnitee.

 

14.2

Indemnification by Sovargen

 

 

Sovargen indemnifies and must keep indemnified Kazia, it Affiliaties and their respective officers, directors, agents and employees (Kazia Indemnitees) against all Claims that may be brought against a Kazia Indemnitee or which a Kazia Indemnitee may pay, sustain or incur as a result of any one or more of the following:

 

  (a)

gross negligence or wilful misconduct or material failure to comply with applicable Laws by Sovargen;


27

 

  (b)

any breach by Sovargen of the representations or warranties under clauses 13.1 or 13.2; or

 

  (c)

the Development or Manufacture of the Compound or the Product, or Commercialisation of the Product, by or on behalf of Sovargen, its Affiliates or sub-licensees,

 

 

except, in each case, to the extent such Claim arises from any act or omission of a Kazia Indemnitee.

 

14.3

Mitigation of loss

 

 

Each party will take and will procure that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the other party may reasonably require in order to mitigate any Claims (or potential losses or damages) under this clause 14. Nothing in this Agreement will or will be deemed to relieve any party of any common law or other duty to mitigate any losses incurred by it.

 

14.4

Limitation of liability

 

 

Subject to clause 14.5, neither party is liable to the other party or to any other person for any Consequential Loss arising out of or in connection with this Agreement irrespective of whether:

 

  (a)

the liability for the loss or damage arises in or under contract (including for liability under any indemnity), statute, tort (including negligence), equity or otherwise at Law; or

 

  (b)

it is notified of the possibility of that potential loss or damage.

 

14.5

Exclusions

 

 

Nothing in this Agreement operates to exclude a party’s liability for:

 

  (a)

personal injury or death;

 

  (b)

breach of confidentiality obligations under clause 10;

 

  (c)

any fraudulent acts or omissions; or

 

  (d)

any reckless or malicious acts.

 

15.

Insurance

 

15.1

Parties obligation to insure

 

 

Each party must effect and maintain through the Term and for a period of 7 years thereafter, at its own expense, any insurances that a reasonable and prudent person engaged in the relevant industry would effect and maintain to satisfy the indemnity obligations under this Agreement (including with respect to minimum coverage), including, in the case of Sovargen:

 

  (a)

product liability insurance; and

 

  (b)

primary clinical trial insurance.

 

15.2

Evidence of currency

 

  (a)

Each party must provide to the other party as soon as practicable and, where possible, at least 30 days prior to such event, written notice of any cancellation, non-renewal or material change in any of the insurance policies required to be held by that party pursuant to clause 15.1.


28

 

  (b)

On each anniversary of the Effective Date, each party must provide renewal certificates to the other party in relation to the insurance policies required to be held by that party pursuant to clause 15.1.

 

16.

Term and termination

 

16.1

Term

 

 

This Agreement will commence upon the Effective Date and will continue in full force and effect until the expiration of the last to expire Royalty Term, unless terminated earlier in accordance with its terms (Term).

 

16.2

Termination for insolvency

 

 

To the greatest extent permissible by Law, either party may terminate this Agreement (in whole) immediately by written notice if the other party is subject to an Insolvency Event.

 

16.3

Termination for breach

 

  (a)

If a party considers that the other party (Defaulting Party) has materially breached the Agreement, then it may give a notice (Default Notice) to the Defaulting Party specifying the breach and requiring the Defaulting Party to remedy the breach within 60 days after the Default Notice is given to the Defaulting Party.

 

  (b)

Subject to clause 16.3(c), a party may terminate this Agreement (either in whole or on a country-by-country basis) immediately by written notice to the Defaulting Party in circumstances where the Defaulting Party received a Default Notice and failed to comply with that Default Notice within the relevant period referred to in clause 16.3.

 

  (c)

If the Defaulting Party disputes the existence, materiality or cure of the alleged breach, the other party will not have a right to terminate this Agreement until it has been determined pursuant to clause 17 that the Defaulting Party did materially breach the Agreement, and such Defaulting Party further fails to cure such breach within 30 days after the conclusion of that dispute resolution procedure.

 

16.4

Termination where Development or Commercialisation deemed unviable

 

 

At any time during the Term, if Sovargen considers that the Development or Commercialisation of the Product in the Field in the Territory is unviable, Sovargen may request to terminate this Agreement (either in whole or on a country-by-country basis) by providing written notice to Kazia. The parties must discuss any such notice in good faith and following reasonable efforts to remediate, either party may terminate this Agreement (either in whole or on a country-by-country basis as requested by Sovargen in its notice) by providing notice of termination to the other party, which notice includes an effective date of termination at least 30 days after the date of the notice.

 

16.5

Termination by Sovargen

 

 

Sovargen may immediately terminate this Agreement (in whole or on a country-by-country basis) on written notice to Kazia if Kazia materially breaches any of its representations or warranties given under clause 13.1 or 13.3.

 

16.6

Termination by Kazia

 

 

Notwithstanding any other provision of this Agreement, Kazia may immediately terminate this Agreement (in whole or on a country-by-country basis) on written notice to Sovargen:

 

  (a)

in accordance with clause 4.1(f); or

 

  (b)

if Sovargen materially breaches any of its representations or warranties given under clause 13.1 or 13.2; or

 

  (c)

if Sovargen fails to use Commercially Reasonable Efforts to satisfy any Development Milestone Event specified in column 1 of the table set out in Schedule 3.


29

 

16.7

General consequences of termination

 

 

Subject to clauses 16.8, 16.9 and 16.10, on the expiry or termination of this Agreement, this Agreement is at an end as to its future operation except for the enforcement of any right or claim that arises on, or has arisen before, the expiry or termination.

 

16.8

Termination of Genentech Agreement

 

  (a)

To the extent possible, upon the early termination of the Genentech Agreement for any reason, this Agreement will continue in full force and effect, provided that:

 

  (i)

all rights and licenses granted by Kazia under clause 2.1 to any Licensed IP which Kazia obtained Control of through a licence from Genentech under the Genentech Agreement shall terminate; and

 

  (ii)

all necessary consequential amendments to this Agreement will be taken to have been made (including with respect to applicable representations and warranties) with effect on and from the date upon which the Genentech Agreement terminates.

 

  (b)

During the Term of this Agreement, Kazia shall, at its own cost and expense, use best efforts to maintain the Genentech Agreement in full force and effect and shall not terminate, amend, waive or otherwise modify (or consent to any of the foregoing) its rights under the Genentech Agreement in any manner that materially diminishes the rights or licenses granted to Sovargen hereunder, without first notifying Sovargen and shall obtain Sovargen’s consent (not to be unreasonably withheld). If despite of Kazia’s best efforts, the Genentech agreement is terminated, Kazia shall use best efforts to assist Sovargen to obtain a direct license from Genentech. Where Sovargen obtains a direct licence from Genentech, Sovargen is no longer obliged to make any payments to Kazia other than the payments specified in clause 16.9 (c)-(i). For the avoidance of doubt, in no circumstances will Kazia be obliged to make any payment to Genentech under such direct licence.

 

16.9

Specific consequences of termination

 

  (a)

Upon the expiration of the Term of this Agreement:

 

  (i)

Sovargen must pay to Kazia any unpaid invoices submitted before termination or any invoices submitted by Kazia after termination in relation to royalties or other payments accrued before termination and due in accordance with clauses 5 or 6;

 

  (ii)

the licences and rights granted by Kazia under clause 2.1 will covert to perpetual and fully paid-up non-exclusive licenses; and

 

  (iii)

Sovargen may continue conducting activities with respect to the Manufacture and Commercialisation of the Products in the Field in the Territory.

 

  (b)

Upon the early termination of this Agreement pursuant to clause 16.4 or by Kazia pursuant to clause 16.2, clause 16.3 or clause 16.6, either in whole or with respect to a country in the Territory, when the Agreement is terminated, in whole or with respect to that country:

 

  (i)

all licences and rights granted under this Agreement will immediately terminate;

 

  (ii)

Sovargen must pay to Kazia any unpaid invoices submitted before termination or any invoices submitted by Kazia after termination in relation to royalties or other payments accrued before termination and due in accordance with clauses 5 or 6;

 

  (iii)

Sovargen must discontinue making any representations regarding its status as a licensee of Kazia for the Products in the country or the Territory (as is applicable);

 

  (iv)

Sovargen must, to the extent permitted by Law, transfer and assign to Kazia all of Sovargen’s right, title and interest in and to any and all Regulatory Approvals for the Products. Notwithstanding the foregoing, if Kazia terminates this Agreement in accordance with clause 16.6 and Sovargen makes such transfer and assignment, Kazia shall reimburse Sovargen for the costs incurred by Sovargen to obtain the Regulatory Approvals after the parties discuss the reimbursement amount in good faith;


30

 

  (v)

Sovargen at Kazia’s expense and upon reimbursing Sovargen’s out-of-pocket expenses for patent prosecution, must transfer the prosecution and maintenance of such Licenced Patents in the country or the Territory (as is applicable) to Kazia if it, at any time during the Term, became responsible for in accordance with clause 11.1(c);

 

  (vi)

Sovargen must provide Kazia with copies of any data and results generated from clinical trials and other studies of the Product in the Field that are in progress at the time of the early termination but which were not previously provided to Kazia by Sovargen;

 

  (vii)

Sovargen must cease conducting any activities with respect to Development, Manufacture or Commercialisation of any Products in the Territory or applicable country in the Territory;

 

  (viii)

at Kazia’s reasonable request and cost, Sovargen must:

 

  (A)

provide assistance to Kazia as may be reasonably necessary or useful for Kazia to commence or continue the Development, Manufacture or Commercialisation of the Product in the Field in the Territory for a period of at least 6 months after the effective date of termination; and

 

  (B)

to the extent Sovargen is performing or having performed such activities, transferring or amending as appropriate, any contracts with Third Parties for services related to the Development, Manufacture or Commercialisation of the Product in the Field in the Territory or, if such contract is not assignable to Kazia, cooperate with Kazia in its efforts to obtain such services from such Third Party; and

 

  (ix)

at Kazia’s reasonable request, Sovargen must sell all or part of the inventory of the Compound and the Product held by Sovargen in the Territory or with respect to the applicable country in the Territory as at the effective date of termination at a price equal to the cost paid by Sovargen for such inventory (or Sovargen’s manufacturing cost if such inventory is manufactured by Sovargen itself) Notwithstanding the foregoing, Kazia is responsible for any costs incurred in relation to the shipping and handling of such inventory by Sovargen at the request of Kazia.

 

  (c)

Upon the early termination of this Agreement by Sovargen pursuant to clause 16.2, clause 16.3 or clause 16.5:

 

  (i)

Sovargen must pay to Kazia any unpaid invoices submitted before termination or any invoices submitted by Kazia after termination in relation to royalties or other payments accrued before termination and due in accordance with clauses 5 or 6; and

 

  (ii)

Kazia shall use best efforts to assist Sovargen to obtain a direct licence from Genentech and

 

  (A)

where Sovargen obtains a direct licence from Genentech, Sovargen is no longer obliged to make any payments to Kazia other than the payments specified in clause 16.9 (c)-(i). For the avoidance of doubt, in no circumstances will Kazia be obliged to make any payment to Genentech under such direct licence; and

 

  (B)

where Sovargen is unable to obtain a direct licence from Genentech, subject to the Genentech Agreement remaining in force, all licences and rights granted by Kazia to Sovargen pursuant to this Agreement will survive termination subject to Sovargen’s continued payment of all royalties or other payments due in accordance with clauses 5 or 6, provided that where the Agreement is terminated by Sovargen pursuant to clause 16.3 or clause 16.5, Sovargen is not required to make such payments until the material breach is cured by Kazia.


31

 

16.10

Clauses surviving termination

 

 

Despite any other provision of this Agreement, clauses 1, 2.1(c), 5.2, 6, 8, 9, 10, 14, 15, 16.7, 16.9, 16.10 and 18 survive the expiry or termination of this Agreement.

 

17.

Dispute resolution

 

17.1

Delivering a Dispute Notice

 

 

If any dispute, controversy or claim arises between the parties arising out of, relating to or in connection with this Agreement, including any question regarding its existence, validity or termination (Dispute), a party may deliver to the other party a written notice (Dispute Notice) which sets out:

 

  (a)

the nature of the Dispute; and

 

  (b)

the relief or remedy that the party seeks.

 

17.2

Parties must negotiate

 

  (a)

During the period of 20 Business Days after delivery of the Dispute Notice, or any longer period agreed in writing by the parties (Initial Period), each of the parties must use their reasonable endeavours and act in good faith to resolve the Dispute by discussion and negotiation.

 

  (b)

If the parties are unable to resolve the Dispute within the Initial Period, then the Dispute must be referred to a senior representative or executive officer of each of the parties with authority to settle the Dispute, who must, during the period of 20 Business Days after the expiration of the Initial Period, or any longer period agreed in writing by the parties (Further Period), meet with the other representatives and must undertake genuine and good faith negotiation with a view to resolving the Dispute.

 

17.3

Referral to international arbitration

 

  (a)

If the Dispute is not resolved within the Further Period, then such Dispute must:

 

  (i)

if arising from or related to clause 6.5 or 9(e), referred to an Expert and determined in accordance with Schedule 4; or

 

  (ii)

if arising from or related to any clause of this Agreement other than clause 6.5 or 9(e), be resolved by arbitration administered by the Singapore International Arbitration Centre (SIAC) in accordance with the SIAC Rules which are operating at the time the Dispute is referred to arbitration.

 

  (b)

The seat of arbitration must be Singapore.

 

  (c)

The language of the arbitration must be English.

 

  (d)

The arbitration will be conducted by 3 arbitrators mutually agreed by the parties within 30 days after initiation of arbitration. If the parties are unable or fail to agree upon the arbitrators, the arbitrators will be appointed by SIAC.

 

17.4

Other proceedings

 

 

No party may commence any judicial proceedings in relation to the Dispute unless those proceedings are commenced for the purpose of enforcing this clause 17 or to seek interlocutory relief during the Initial Period.


32

 

18.

General

 

18.1

Force majeure

 

 

Where any failure or delay by a party (Affected Party) in the performance of its obligations under this Agreement is caused, directly or indirectly, by a Force Majeure Event:

 

  (a)

the Affected Party must immediately give the other party written notice of that fact;

 

  (b)

the Affected Party is not liable for that failure or delay;

 

  (c)

the Affected Party’s obligations under this Agreement are suspended, to the extent to which they are affected by the relevant Force Majeure Event, for the duration of the Force Majeure Event; and

 

  (d)

if the Force Majeure Event continues for more than 90 consecutive days and while it continues, the party other than the Affected Party may, at its sole discretion, terminate this Agreement by giving written notice to the Affected Party.

 

18.2

Notices

 

 

Any notice or other communication (Notice) to or by a party under this Agreement:

 

  (a)

must be given by personal service, prepaid priority or express post or email;

 

  (b)

must be in writing (and for the purposes of this clause, a Notice in the body of or attached to an email is in writing), legible and in English addressed (depending on the manner in which it is given) as specified below:

 

  (i)

if to Kazia:

 

Address:

  

Three International Towers, Level 24, 300 Barangaroo Avenue, Sydney NSW 2000, Australia

Attention:

  

John Friend

Email:

  

[***]

 

  (ii)

if to Sovargen:

 

Address:

  

2F, 16 Nonhyeon-ro 86-gil, Gangnam-gu, Seoul, 06223

Attention:

  

Cheol-won Park / CEO

Email:

  

[***]

or as otherwise specified in any updated details last notified by the party to the sender by not less than 5 Business Days’ prior to the Notice given in accordance with this clause (Specified Contact Details);

 

  (c)

must be signed by the party’s authorised officer, agent or representative. A party receiving a Notice is not obliged to enquire as to the authority of the person signing the Notice; and

 

  (d)

is deemed to be given by the sender and received by the addressee:

 

  (i)

if delivered in person, when it is left at the recipient’s address set out in the Specified Contact Details;

 

  (ii)

if posted to the recipient’s address set out in the Specified Contact Details, at 9.00 am on the fifth (tenth, if sent to or from an address in another country) business day after the date of posting to the addressee whether delivered or not; or

 

  (iii)

if sent by email, 2 hours after the time the email is sent to the recipient’s email address set out in the Specified Contact Details, as recorded on the sender’s email system, unless the sender receives, within that time period, an automatic notification (other than an out of office message) indicating that the email has not been delivered,

but if the delivery or receipt is on a day which is not a business day or is after 4.00 pm (addressee’s time), it is deemed to have been received at 9.00 am on the next business day.


33

 

 

In this clause, “business day” means a day that is not a Saturday, Sunday or public holiday and on which banks are open for business generally, in the place to which the communication is posted, sent or delivered.

 

18.3

Nature of obligations

 

  (a)

Any provision in this Agreement which binds more than one person binds all of those persons jointly and each of them severally.

 

  (b)

Each obligation imposed on a party by this Agreement in favour of another is a separate obligation. Unless specified otherwise, the performance of one obligation is not dependent or conditional on the performance of any other obligation.

 

18.4

Entire understanding

 

  (a)

This Agreement contains the entire understanding between the parties concerning the subject matter of the Agreement and supersedes, terminates and replaces all prior agreements and communications between the parties.

 

  (b)

Each party acknowledges that, except as expressly stated in this Agreement, that party has not relied on any representation, warranty or undertaking of any kind made by or on behalf of another party in relation to the subject matter of this Agreement.

 

18.5

No adverse construction

 

 

No provision of this Agreement is to be construed to the disadvantage of a party solely because that party was responsible for preparing or proposing this Agreement or the provision.

 

18.6

Further assurances

 

 

A party, at its own expense and within a reasonable time of being requested by another party to do so, must do all things and execute all documents that are reasonably necessary to give full effect to this Agreement.

 

18.7

No waiver

 

  (a)

A failure to exercise, a delay in exercising or partially exercising any power, right or remedy conferred on a party by or in respect of this Agreement does not operate as a waiver by that party of the power, right or remedy.

 

  (b)

A single or partial exercise of the power or right does not preclude a further exercise of it or the exercise of any other power or right under this Agreement.

 

  (c)

A waiver of a breach does not operate as a waiver of any other breach.

 

18.8

Remedies cumulative

 

 

Except as set out in this Agreement, the powers, rights and remedies under this Agreement are cumulative with and not exclusive of any powers, rights and remedies provided by Law independently of this Agreement.

 

18.9

Severability

 

 

Any provision of this Agreement which is invalid in any jurisdiction must, in relation to that jurisdiction, be:

 

  (a)

read down to the minimum extent necessary to achieve its validity, if applicable; and

 

  (b)

severed from this Agreement in any other case,

 

 

without invalidating or affecting the remaining provisions of this Agreement or the validity of that provision in any other jurisdiction.

 

18.10

Successors and assigns

 

 

This Agreement binds and benefits the parties and their respective successors and permitted assigns under clause 18.11.


34

 

18.11

No assignment

 

  (a)

Subject to clauses 18.11(b) and 18.11(c), a party cannot assign or otherwise transfer the benefit of this Agreement without the prior written consent of the other party.

 

  (b)

Kazia may assign or otherwise transfer the benefit of this Agreement to an Affiliate of Kazia.

 

  (c)

Sovargen may assign or otherwise transfer the benefit of this Agreement to an Affiliate of Sovargen.

 

18.12

No variation

 

 

This Agreement cannot be amended or varied except in writing signed by the parties.

 

18.13

Costs

 

 

Each party must pay its own legal costs of and incidental to the preparation and completion of this Agreement.

 

18.14

Conflicting provisions

 

 

If there is any conflict between the main body of this Agreement and any schedules or annexures comprising it, then the provisions of the main body of this Agreement prevail.

 

18.15

No merger

 

 

A term or condition of, or act done in connection with, this Agreement does not operate as a merger of any of the undertakings, warranties and indemnities in this Agreement or the rights or remedies of the parties under this Agreement which continue unchanged.

 

18.16

Operation of indemnities

 

 

Unless this Agreement expressly provides otherwise:

 

  (a)

each indemnity in this Agreement is a continuing obligation and survives the expiry or termination of this Agreement;

 

  (b)

each indemnity given by a party in this Agreement is an additional, separate and independent obligation of the party and no one indemnity limits the operation of any other indemnity; and

 

  (c)

a party may recover a payment under an indemnity in this Agreement before it makes the payment in respect of which the indemnity is given.

 

18.17

No right of set-off

 

 

Unless this Agreement expressly provides otherwise, a party has no right of set-off against a payment due to another party.

 

18.18

Relationship of parties

 

 

Unless this Agreement expressly provides otherwise, nothing in this Agreement may be construed as creating a relationship of partnership, of principal and agent or of trustee and beneficiary.

 

18.19

Counterparts

 

  (a)

This Agreement may be executed in any number of counterparts, each executed by one or more parties.

 

  (b)

All counterparts, taken together, constitute one instrument.

 

  (c)

A party may execute this Agreement by signing any counterpart. To the extent permitted by law, a counterpart may be executed electronically.

 

  (d)

This Agreement is binding on the parties on exchange of counterparts. A copy of a counterpart that is electronically scanned and emailed to each other party or their authorised representative:

 

  (i)

must be treated as an original counterpart;


35

 

  (ii)

is sufficient evidence of the execution of the original; and

 

  (iii)

may be produced in evidence for all purposes in place of the original.

 

18.20

Electronic signatures

 

  (a)

To the extent permitted by law, a party may sign this Agreement electronically, including by using software or a platform for the electronic execution of contracts.

 

  (b)

A print out of the executed Agreement will, once all parties signing electronically have done so, be an executed original counterpart of this Agreement, irrespective of which party prints it.

 

  (c)

Each party that signs this Agreement electronically represents and warrants that it or anyone signing on its behalf:

 

  (i)

has been duly authorised to enter into and execute this Agreement electronically and to create obligations that are valid and binding obligations on the party;

 

  (ii)

has affixed their own electronic signature; and

 

  (iii)

where applicable, holds the position or title indicated under their electronic signature,

and each party is estopped from asserting otherwise.

 

  (d)

No person may challenge the validity of this Agreement by virtue only of the fact that it has been electronically signed by or on behalf of any party.

 

18.21

Governing law and jurisdiction

 

  (a)

This Agreement is governed by, and must be construed in accordance with, the laws of Singapore (Governing Law).

 

  (b)

To the extent permitted by law, the Governing Law governs all matters arising out of or relating to this Agreement or its performance or subject matter, including its execution and formation.

 

  (c)

Each party irrevocably submits to the non-exclusive jurisdiction of courts with jurisdiction in Singapore and irrevocably waives any right to object to the venue for any reason, including that the process has been brought in an inconvenient forum.


36

 

Schedule 1 - Compound

[***]


37

 

Schedule 2 - Licenced Patents in Kazia’s Control as at the Effective Date

[Schedule 2 has been omitted pursuant to the Instructions as to Exhibits of Form 20-F. Schedule 2 contains the patents and patent applications in Kazia’s Control as at the Effective Date comprising the paxalisib patent portfolio.]


38

 

Schedule 3 - Development Milestone payments

 

   

Development Milestone Event

  

Development Milestone Amount (USD)

   
1. First patient dosed as part of any clinical trial of a Product    USD$2,000,000
   
2. First patient dosed as part of any pivotal trial of a Product    USD$[***] to be paid once on the occurrence of Milestone Event 2 or 3, whichever occurs first
   
3. Filing of the first New Drug Application with any Regulatory Authority in the Territory for a Product in the Field    (see Milestone Event 2)
   
4. Obtaining the first Regulatory Approval for a Product in the Field in either the United States of America or a country of the European Union    USD$[***]
   
5. Obtaining a Regulatory Approval for a Product for the first Subsequent Indication in either the United States of America or a country of the European Union    USD$[***]


39

 

Schedule 4 - Expert Determination

[Schedule 4 has been omitted pursuant to the Instructions as to Exhibits of Form 20-F. Schedule 4 sets out the procedures for expert determination of Financial Disputes.]


40

 

Schedule 5 - Agreed press releases

[Schedule 5 has been omitted pursuant to the Instructions as to Exhibits of Form 20-F. Schedule 5 contains the forms of press release agreed by the parties announcing the transaction.]


41

 

Executed as an agreement.

Each signatory confirms that their signature appearing is their personal signature affixed by electronic means and authenticates this document or any counterpart signed by the signatory.

Executed by Kazia Therapeutics Ltd ABN 37 063 259 754 in accordance with section 127(1) of the Corporations Act 2001 (Cth):

 

 /s/ John E. Friend II

  

/s/ Ebru Davidson

 Signature of director

  

Signature of director

 John E. Friend II

  

Ebru Davidson

 Name (please print)

  

Name (please print)

Executed by Sovargen Co, Ltd. in the presence of:

 

 /s/ Eric Maeng

  

/s/ Cheol Won Park

 Signature of witness

  

Signature

 Eric Maeng

  

Cheol Won Park / CEO

 Name of witness (please print)

  

Name (please print)